Amgen (AMGN) Long-Term Investments (2013 - 2014)

Amgen (AMGN) posted Long-Term Investments of $3.4 billion for Q1 2014, little changed on a QoQ basis from $3.4 billion in Q4 2013.

Analysis

Amgen (AMGN) Long-Term Investments (2013 - 2014) Analysis & Trends

Amgen has reported Long-Term Investments for 2 years, with the latest figure at $3.4 billion in Q1 2014.

On a quarterly basis, Long-Term Investments changed N/A year-over-year to $3.4 billion in Q1 2014; TTM through Mar 2014 was $3.4 billion, a N/A change from a year earlier, with the FY2013 full-year figure at $3.4 billion, changed N/A from the prior year.
Long-Term Investments was $3.4 billion for Q1 2014 at Amgen, roughly flat from $3.4 billion in the prior quarter.
The five-year high for Long-Term Investments was $3.4 billion in Q1 2014, with the low at $3.4 billion in Q3 2013.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Amgen	203.97 Bn	189.99 Bn	7.24 Bn	-
2	Gilead Sciences	178.74 Bn	175.56 Bn	6.22 Bn	-
3	Vertex Pharmaceuticals	130.73 Bn	122.88 Bn	2.84 Bn	5.79 Bn
4	Regeneron Pharmaceuticals	80.42 Bn	72.42 Bn	3.93 Bn	9.83 Bn
5	Argenx Se	60.40 Bn	55.21 Bn	1.37 Bn	-4.00 Mn
6	Moderna	57.65 Bn	52.52 Bn	52.00 Mn	1.77 Bn
7	Alnylam Pharmaceuticals	33.37 Bn	30.07 Bn	992.69 Mn	22.17 Mn
8	Biogen	32.15 Bn	30.86 Bn	1.96 Bn	-
9	Roivant Sciences	29.58 Bn	29.58 Bn	1.16 Mn	-
10	Insmed	28.06 Bn	26.90 Bn	358.27 Mn	-

Historic Data

Download Data